Publicacións (106) Publicacións de Javier García Seara

2024

  1. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction

    Biochemical Pharmacology, Vol. 230

  2. Characterization of patients with extensive left atrial myopathy referred for atrial fibrillation ablation: incidence, predictors, and outcomes

    Clinical Research in Cardiology

  3. Effect of age on clinical impact and mid-term denervation in patients undergoing cardioneuroablation

    Scientific Reports, Vol. 14, Núm. 1

  4. Human recombinant relaxin-2 (serelaxin) regulates the proteome, lipidome, lipid metabolism and inflammatory profile of rat visceral adipose tissue

    Biochemical Pharmacology, Vol. 223

  5. Impact of initiation of SGLT2 inhibitor treatment on the development of arrhythmias in patients with implantable cardiac devices

    Revista Espanola de Cardiologia, Vol. 77, Núm. 6, pp. 481-489

  6. Prognostic value of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio in cardiac amyloidosis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 634-644

  7. Pseudotransposition of the great leads

    PACE - Pacing and Clinical Electrophysiology, Vol. 47, Núm. 2, pp. 233-235

2023

  1. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study

    ESC Heart Failure, Vol. 10, Núm. 5, pp. 3055-3066

  2. Circulating miR-451a Expression May Predict Recurrence in Atrial Fibrillation Patients after Catheter Pulmonary Vein Ablation

    Cells, Vol. 12, Núm. 4

  3. Clinical and cost-effectiveness results of an on-call program for pacemaker implantations

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 936-937

  4. Left bundle branch area pacing in a patient with right bundle branch block and heart failure.

    Medicina Clinica Practica, Vol. 6, Núm. 3

  5. Patient selection, peri-procedural management, and ablation techniques for catheter ablation of atrial fibrillation: an EHRA survey

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 25, Núm. 2, pp. 667-675

  6. Plasma miR-486-5p Expression Is Upregulated in Atrial Fibrillation Patients with Broader Low-Voltage Areas

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  7. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  8. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General Registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 4

  2. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

    European Journal of Internal Medicine, Vol. 99, pp. 45-56

  3. Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 2, pp. 202-210

  4. Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy

    Cells, Vol. 11, Núm. 2

  5. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

    BMC Medicine, Vol. 20, Núm. 1